NPPB and cancer: In current cardio-oncological guidelines, cardiac biomarkers such as cardiac troponins (cTn) and natriuretic peptides (BNP, brain natriuretic peptide, and NT-proBNP, N-terminal pro-B-type natriuretic peptide) are recommended to monitor cardiac function during cancer treatment and diagnose cancer therapy-related cardiac dysfunction (CTRCD) [3].